| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_219f863c3f9ccb2e751965f194956649 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2014-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb52aca9aa32af36ccc85b8baaf13ec8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b665c909e749a84a2a55ae169941278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d43c67e7c7108dd7928f7cbfc89546d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afe583d40d874d0aab37fbcbb7edc8e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02e83d4c6c4827008eee4cca135e4d18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5cb113fd7f660612bb239d812f82852
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e155e60f0896668aeab2d16cbc32314 |
| publicationDate |
2016-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-106029104-A |
| titleOfInvention |
Metallo-beta-lactamase (MBL) inhibitors containing a zinc chelating moiety |
| abstract |
The present invention provides compounds according to formula I: A-L-B, in which A represents a lipophilic chelating moiety selective to Zn ions ; L is a covalent bond or a linker; B is a carrier, which is Moieties capable of interacting with one or more biological structures found in bacteria (preferably bacterial cell walls) (for example penicillin binding proteins such as metallo-β-lactamases or DD-transferases) or capable of enhancing the compound's ability to cross bacterial cell membranes transport part. Such compounds find use in methods of treatment and/or prophylaxis of bacterial infections in humans or non-human mammals. In such methods, the compound of formula I may be administered in combination (simultaneously, separately or sequentially) with a beta-lactam antibiotic. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110573507-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111718361-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111718361-B |
| priorityDate |
2013-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |